Physician profile

Erdal Sarac

Nephrology (Internal Medicine) · Poland, OH

NPI 1821072752

$8,664.36

in general payments reported to CMS, 2019-2025

39 companies · none reported in 2025

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,117.34
Education$2.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $865.78 2019-2024 Farxiga
Vifor Pharma, INC. $837.75 2019-2023 Veltassa, Korsuva
Horizon Therapeutics Plc $737.03 2021-2023 Krystexxa
Opko Pharmaceuticals, LLC $564.16 2019-2024 Rayaldee
Amgen INC. $555.45 2019-2024 Krystexxa, Tavneos
Daiichi Sankyo INC. $421.04 2019-2024 Injectafer
Otsuka America Pharmaceutical, INC. $399.09 2019-2024 Jynarque
Calliditas Therapeutics US INC. $386.71 2022-2024 Tarpeyo
Aurinia Pharma U.S., INC. $380.23 2021-2024 Lupkynis
Nxstage Medical, INC. $341.74 2019-2023 Liberty Select Cycler, Nxstage System One
Bayer Healthcare Pharmaceuticals INC. $338.35 2021-2024
Mallinckrodt Hospital Products INC. $279.18 2020-2023 Acthar, Terlivaz
Glaxosmithkline, LLC. $256.09 2021-2024 Benlysta
Baxter Healthcare $196.15 2019-2021
Novartis Pharmaceuticals Corporation $180.00 2019-2024
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Outset Medical INC $164.07 2023
Bard Peripheral Vascular, INC. $148.70 2019
Mallinckrodt Enterprises LLC $140.51 2019
Travere Therapeutics, INC. $136.26 2019-2024
Alexion Pharmaceuticals, INC. $121.78 2019-2022
Ardelyx, INC. $107.08 2024 Ibsrela
Renalytix Ai, INC. $104.76 2022-2023 Kidneyintelx Blood Collection Convenience Kit
Ultragenyx Pharmaceutical INC. $99.14 2021-2022
Novo Nordisk INC $98.83 2022-2024 Ozempic, Rybelsus
Fresenius USA Marketing, INC. $96.11 2019-2024 Velphoro
Akebia Therapeutics INC $94.86 2019
Gilead Sciences, INC. $83.34 2023 Veklury
Takeda Pharmaceuticals U.S.A., INC. $83.19 2021-2022
Otsuka Pharmaceutical Development & Commercialization, INC. $72.96 2019-2024
Genzyme Corporation $56.45 2019-2022
Janssen Biotech, INC. $49.18 2019
Janssen Pharmaceuticals, INC $48.88 2019-2020
Ani Pharmaceuticals, INC. $44.59 2024 Purified Cortrophin Gel
Amag Pharmaceuticals, INC. $41.25 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $34.66 2023-2024 Jardiance
Hikma Pharmaceuticals USA $29.51 2019
Biomerieux INC $27.27 2024 Vidas Nephrocheck
Alnylam Pharmaceuticals INC. $23.74 2023 Oxlumo
Arbor Pharmaceuticals, INC. $18.49 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$15,100.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Erdal Sarac

$8,664.36

in general payments reported 2019-2025

Years
2019-2024
Top company
Opko Pharmaceuticals, LLC

https://glasscript.com/doctor/82176/erdal-sarac

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.